Abstract: FR-PO885
The Impact of Gender Affirming Hormone Therapy on Measures of Kidney Function: A Systematic Review and Meta-Analysis
Session Information
- Diversity and Equity in Kidney Health - II
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Diversity and Equity in Kidney Health
- 800 Diversity and Equity in Kidney Health
Authors
- Collister, David Thomas, University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
- Krupka, Emily, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Ferguson, Thomas W., University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Whitlock, Reid, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Millar, Adam C., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Dahl, Mashall, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada
- Fung, Raymond, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Ahmed, Sofia B., University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
- Tangri, Navdeep, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Walsh, Michael, McMaster University, Hamilton, Ontario, Canada
Background
Gender affirming hormone therapy (GAHT) modifies body composition and lean muscle mass in transgender persons. We sought to characterize the change in serum creatinine, other kidney function biomarkers, and glomerular filtration rate (GFR) in transgender persons initiating masculinizing and feminizing GAHT.
Methods
We searched PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov from inception to September 16, 2020 for randomized controlled trials, observational studies, and case series that evaluated the change in serum creatinine, other kidney function biomarkers, and GFR before and after the initiation of GAHT in adult transgender persons. Two reviewers independently screened and abstracted data and disagreements were resolved by a third reviewer. Random effects meta-analysis was performed to determine the change in outcomes over follow-up of 3, 6 and 12 months.
Results
Of the 4758 eligible studies, 26 met the inclusion criteria including 9 studies that recruited 488 transgender men and 593 women in which data was meta-analyzed. There was heterogeneity in study design, populations, GAHT routes, and dosing. At 12 months after initiating GAHT, serum creatinine increased by 0.15mg/dL (95% CI 0.00, 0.29) in 370 transgender men and decreased by -0.05mg/dL (95% CI -0.16, 0.05) in 361 transgender women. No study reported the impact of GAHT on albuminuria, proteinuria, cystatin C, or measured GFR.
Conclusion
GAHT increases serum creatinine in transgender men and does not impact serum creatinine in transgender women. The impact on GAHT on other kidney function biomarkers and measured GFR is unknown.